Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/26/2025

Anticoagulation Management in Subdural Hematoma

Immediate Reversal of Anticoagulation

  • For any patient with an acute subdural hematoma (SDH) who is anticoagulated, reverse coagulopathy promptly with prothrombin complex concentrate (PCC) plus vitamin K; PCC normalizes INR within ~15 minutes and is preferred in most national guidelines. 1
  • An elevated INR > 3.0 is associated with significantly larger hematoma volumes and a higher risk of expansion. 1
  • Approximately 30–40 % of intracranial hemorrhages enlarge during the first 12–36 hours, and this expansion is prolonged when the patient is on anticoagulation. 1, 2, 3
  • Vitamin K must be administered together with PCC (or fresh‑frozen plasma) to sustain the reversal effect. 1
  • Routine platelet transfusion for patients on antiplatelet agents is not recommended, as it increases the odds of death or dependence. 4

Risk of Hematoma Expansion While Anticoagulated

  • Patients on anticoagulation have a markedly increased likelihood of hematoma growth, especially when INR is markedly elevated, underscoring the need for rapid reversal. (Evidence from prospective cohort data.) 1

Anticoagulation Resumption After SDH

  • All anticoagulants and antiplatelet agents should be held for at least 1–2 weeks after the hemorrhagic event. 3, 6
  • The risk of a thrombo‑embolic (ischemic) event during anticoagulant cessation is about 2.1 % within the first 30 days. 1, 7
  • The median safe interval off warfarin is 10 days; no ischemic strokes were reported when therapy was resumed up to 19 days after the bleed. 1, 2, 7
  • For patients with mechanical heart valves, the cessation‑related ischemic risk is ≈2.9 %; for those with atrial fibrillation and a prior embolic stroke, the risk is ≈2.6 %. 1, 7
  • If anticoagulation must be restarted early (after 3–4 weeks), intravenous heparin is considered safer than oral agents. 3, 6
  • When oral anticoagulation is resumed, target the lower end of the therapeutic INR range to balance bleeding and thrombotic risks. 6
  • Anticoagulation should not be resumed for lobar SDH when cerebral amyloid angiopathy is suspected, due to a higher recurrence risk. 3, 6

Special Considerations

Thrombocytopenia

  • Therapeutic low‑molecular‑weight heparin (LMWH) can be given if the platelet count is maintained > 50 × 10⁹/L. 8
  • A half‑dose of LMWH is acceptable for platelet counts between 20–50 × 10⁹/L. 8
  • Therapeutic anticoagulation should be held when platelets fall below 20 × 10⁹/L. 8

Hemorrhagic Transformation vs. Primary Intracerebral Hemorrhage

  • In cases of hemorrhagic transformation of an ischemic stroke, anticoagulation may be continued if the bleed is asymptomatic and not enlarging. 6
  • Each situation requires individualized assessment of bleed size, clinical symptoms, and the underlying indication for anticoagulation. 6

REFERENCES